Abstract:Abstract The mammalian target of rapamycin (mTOR) is an important target for cancer chemotherapy due to the deregulation of its signaling pathway in a wide spectrum of human tumors. mTOR exists in at least two functional protein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). While rapamycin and its analogs (rapalogs) inhibit only mTORC1, ATP-competitive inhibitors of mTOR target both mTORC1 and mTORC2 and therefore have the potential for improved anticancer efficacy. We have previously reported on the pyrazolopyrimidine series of ATP-competitive mTOR inhibitors (J. Med. Chem. 2009, 52, 5013 – 5016). We now report that derivatization of the morpholine ring in these inhibitors leads to greatly enhanced mTOR selectivity versus PI3K. Selective mTOR inhibitors have the potential to achieve a higher therapeutic index in the clinic due to better tolerability. Testing these inhibitors in tumor cells and evaluating the most potent analogs in human tumor xenograft models in the nude mouse led to the identification of WYE-125132, a candidate for clinical development. WYE-125132 is also selective versus a wide range of other kinases including the closely-related PIKKs. Detailed structure activity relationships in the pyrazolopyrimidine series will be presented. In conclusion, modification of the morpholine ring of a series of pyrazolopyrimidines leads to analogs with enhanced mTOR selectivity over PI3K and potent efficacy in human tumor xenograft models in the nude mouse. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B145.

Synthesis and Structure-Activity Relationships of Ring-Opened 17-Hydroxywortmannins: Potent Phosphoinositide 3-Kinase Inhibitors with Improved Properties and Anticancer Efficacy.

Pegylated Wortmannin and 17-Hydroxywortmannin Conjugates As Phosphoinositide 3-Kinase Inhibitors Active in Human Tumor Xenograft Models

Small Molecules Targeting Phosphoinositide 3-Kinases

Hybrid Inhibitors of Phosphatidylinositol 3-Kinase (PI3K) and the Mammalian Target of Rapamycin (mtor): Design, Synthesis, and Superior Antitumor Activity of Novel Wortmannin-Rapamycin Conjugates.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Antitumor Agents 295. E-ring Hydroxylated Antofine and Cryptopleurine Analogues As Antiproliferative Agents: Design, Synthesis, and Mechanistic Studies.

Synthesis and Sar of Novel 4-Morpholinopyrrolopyrimidine Derivatives As Potent Phosphatidylinositol 3-Kinase Inhibitors

1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism

Enantioselective Total Synthesis of (+)-Wortmannin.

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Design, synthesis and antitumor effects of novel benzimidazole derivatives as PI3K inhibitors

Identification of Novel Piperazinylquinoxaline Derivatives As Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors

Wortmannin Inhibits Cell Growth and Induces Apoptosis in Colorectal Cancer Cells by Suppressing the PI3K/AKT Pathway

Bis(Morpholino-1,3,5-Triazine) Derivatives: Potent Adenosine 5 '-Triphosphate Competitive Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (Pki-587), A Highly Efficacious Dual Inhibitor

Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors

Novel Nitrogen-Enriched Oridonin Analogues with Thiazole-Fused A-Ring: Protecting Group-Free Synthesis, Enhanced Anticancer Profile, and Improved Aqueous Solubility

Synthesis and biological evaluation of analogues of AKT (protein kinase B) inhibitor-IV.

Discovery of Novel 2-Piperidinol-3-(arylsulfonyl)quinoxalines As Phosphoinositide 3-Kinase Α (pi3kα) Inhibitors

Abstract B145: Highly Selective Pyrazolopyrimidine Mtor Inhibitors with Profound in Vivo Antitumor Activity

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors